Please login to the form below

Ablynx

This page shows the latest Ablynx news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

Prior to its takeover, Ablynx had suggested peak sales of more than 1bn were possible. ... It is the first drug to be approved for marketing based on Ablynx’s ‘nanobody’ technology, a new class of therapeutic proteins based on single-domain

Latest news

Neoantigen player Achilles gets OK for first clinical trial

at Ablynx before it was sold to Sanofi last year for $4.8bn – took over as chair of the UK biotech. ... The company has made no secret of its intention to follow an Ablynx-like path and become an integrated biotech focused on developing and
Duchenne UK backs Evox dystrophin delivery project

de Fougerolles, who joined the company last year from Ablynx.
AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

Meanwhile, new candidates for treating established RSV infections are also coming through the pipeline, with Sanofi’s Ablynx unit expecting phase 2b results for ALX-0171 before the end of the
Sanofi swaps execs with Bayer, looks to staunch diabetes, cardio decline

The EMA has just approved its acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi, the main asset behind its 9.3bn acquisition of Belgian biotech Ablynx, with an FDA decision expected in
Redmile and Google help Evox raise £35.5m for exosome pipeline

Evox spun out of Oxford in 2016 with £10m in seed funding, with de Fougerolles – who was previously chief scientific officer of Ablynx before its 9.3bn takeover by Sanofi earlier

More from news
Approximately 8 fully matching, plus 31 partially matching documents found.

Latest Intelligence

30 Women Leaders in UK Healthcare (part 2)

corporate roles for Vertex and Ablynx.
Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.
Deal Watch November 2015

410. Ablynx. Novo Nordisk. Discovery collaboration, licence. Multi specific Nanobody drug candidates in undisclosed TA with option to expand to second Nanobody programme.
Deal Watch table for February 2014

25, 000. Ablynx / Merck &Co. Collaboration. Nanobody candidates to target “immune checkpoint modulators”.
Pharma deals during February 2014

It is has been a busy month for Merck &Co. Belgian-based Ablynx has signed a second exclusive collaboration and licensing deal with the company to focus on the discovery and ... Under the terms of the agreement, Ablynx will receive an upfront payment of

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

PureTech Health appoints new chief financial officer

Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
Apitope strengthens its board with new director

He has also served on several boards including Ablynx, Evotec and Acambis.
Ablynx reshuffles its board again

Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman. ... Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable
Robert Freisen joins Ablynx

Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities. ... He said: “I have long admired Ablynx and am excited to join
Novo Nordisk target Ablynx reshuffles its board

Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk. ... Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured)